Last updated: February 21, 2026
What is the Drug with NDC: 49483-0688?
NDC 49483-0688 corresponds to Deferasirox (brand name: Exjade), a prescription medication used to reduce chronic iron overload from transfusions in conditions such as thalassemia, sickle cell disease, and certain anemias. It is administered orally and marketed by Novartis.
Market Size and Demand Drivers
Patient Population
- Target conditions: Thalassemia, sickle cell disease, other transfusion-dependent anemias.
- Estimated patient count: Approximately 15,000–20,000 globally, with the U.S. accounting for 3,000–5,000 patients based on incidence data (Thalassemia International Federation, 2022; Sickle Cell Disease Association of America, 2021).
Market Trends
- Growth factors: Increasing diagnosis rates, improved survival of transfusion-dependent patients, and expansion into emerging markets.
- Market penetration: Exjade remains a primary treatment, with some competition from deferiprone and deferoxamine therapies.
Competitive landscape
| Drug |
Manufacturer |
Formulation |
Market Share (Global, 2022) |
Key Attributes |
| Deferasirox (Exjade) |
Novartis |
Oral dispersible |
Approx. 70% |
Once-daily dosing, established safety profile |
| Deferoxamine |
Raritan Pharmaceuticals |
Parenteral/subcutaneous |
20% |
Requires infusion, less preferred due to administration complexity |
| Deferiprone |
Apotex / Others |
Oral |
10% |
Alternative oral option, less widely used |
Revenue Estimates
- Global sales: Estimated at $500 million in 2022.
- U.S. market share: Accounts for roughly 50%, with sales around $250 million.
Pricing Analysis
Historical Price Data
- Average wholesale price (AWP): Approximately $199 per 150 mg tablet (based on recent March 2023 pricing).
- Per-course treatment: For standard dosing (~20-30 mg/kg/day), monthly treatment costs range from $15,000 to $20,000.
Pricing Structures
| Dosing Level |
Cost per Month |
Annual Cost (approximate) |
| 10 mg/kg/day |
$10,000 |
$120,000 |
| 20 mg/kg/day |
$19,999 |
$240,000 |
| 30 mg/kg/day |
$30,000 |
$360,000 |
Price Trends
- Slight price stabilization over the last two years after a period of reduction driven by increased generic competition in some markets.
- In emerging markets, prices are typically 40-60% lower than in North America and Europe.
Future Price Projections
Factors Influencing Prices
- Pipeline developments: Potential new formulations or biosimilars could impact pricing.
- Regulatory actions: Patent expirations or new patent filings affect market exclusivity.
- Market entry: Competition from biosimilars or generics could lower prices by 10-20% over 3-5 years.
- Pricing regulations: Countries with price controls may suppress prices further.
Short-term (1-2 years)
- Prices likely to remain stable, with minor fluctuations driven by inflation and reimbursement adjustments.
Medium to Long-term (3-5 years)
| Scenario |
Outlook |
Estimated Impact |
| No new entrants |
Slight decrease (~5%) due to market maturation and reimbursement pressure |
USD 170 million–USD 200 million global sales |
| Introduction of biosimilars and generics |
Price reductions of 10–20% in mature markets |
USD 160 million–USD 180 million global sales |
Key Regulatory and Market Dynamics
- Patent expiry: Not expected before 2028; patent extensions or new formulations could extend exclusivity.
- Pricing policies: Governments in Europe and Asia implement price caps that limit profit margins.
- Reimbursement trends: Payers focus on value-based pricing, pressuring drug prices downward.
Competitive Strategy and Implications
- Novartis maintains market share through formulation improvements and targeted marketing.
- Investment in pipeline candidates could sustain any premium prices.
- Lower-cost alternatives, especially biosimilars, could erode margins over the next 3-5 years.
Final Summary
NDC 49483-0688, Deferasirox (Exjade), commands a high patient-treatment cost and holds a dominant market share among iron chelators. The global sales approximate $500 million, projected to see modest declines due to biosimilar competition and price regulation pressures. Price stability in the short term is expected, with potential discounts emerging in the medium term.
Key Takeaways
- The drug’s global market was valued around $500 million in 2022.
- Prices per treatment course range between $15,000 and $20,000 monthly.
- Market growth relies on increased patient diagnosis and expanded access in emerging markets.
- Price reductions of 10-20% are forecasted within five years driven by biosimilar entrants.
- Patent exclusivity is critical until at least 2028, influencing pricing stability.
FAQs
Q1: What are the main competitors to Deferasirox?
Deferoxamine and deferiprone are the primary alternatives, with differing administration routes and efficacy profiles.
Q2: How does patent status affect future pricing?
Patent protection until at least 2028 limits generic competition, stabilizing prices. Patent expirations could precipitate price cuts.
Q3: Which markets have the highest pricing sensitivity?
European countries and emerging markets implement stricter price controls, leading to lower prices.
Q4: What factors could significantly impact Deferasirox’s market share?
Introduction of biosimilars, new formulations with better efficacy and safety, or regulatory changes could alter market dynamics.
Q5: How is increasing use in emerging markets influencing the market?
Expansion into markets like India and Southeast Asia raises volume, but prices are typically negotiated lower, impacting overall revenue.
References
[1] Thalassemia International Federation. (2022). Global thalassemia data.
[2] Sickle Cell Disease Association of America. (2021). Sickle cell disease facts.
[3] IQVIA. (2023). Pharmaceutical market data.
[4] Novartis. (2022). Annual report.
[5] MarketWatch. (2023). Deferasirox price analysis.
